Peregrine Pharmaceuticals' anti-PS Technology Platform to Be Discussed at AIDS Vaccine 2008 Conference

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial

Nasdaq Panel Grants Peregrine Pharmaceuticals' Request for 180-Day Extension for Continued Listing on Nasdaq

Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009

Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008

Peregrine Pharmaceuticals to Report Fiscal Year 2008 Financial Results

Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer